Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality

Biological, clinical and population relevance of 95 loci for blood lipids

Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · see citing works

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · see citing works

Effects of torcetrapib in patients at high risk for coronary events

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · see citing works

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · see citing works

Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial

Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707 · see citing works

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., & Zukel, W. J. (1977) · Circulation · doi:10.1161/01.cir.55.5.767 · Cited by 1,492 · see citing works

THE TROMSØHEART-STUDY

Miller, N. E., Thelle, D. S., Førde, O. H., & Mjøs, O. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92274-7 · Cited by 1,206 · see citing works

Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis A Randomized Controlled Trial

Tardif, J. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 724 · see citing works

Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis

Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724 · see citing works

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · see citing works

Molecular regulation of HDL metabolism and function: implications for novel therapies

Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 603 · see citing works

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.

Plump, A. S., Scott, C., & Breslow, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9607 · Cited by 569 · see citing works

miR-33 links SREBP-2 induction to repression of sterol transporters

Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562 · see citing works

The Tromsø Heart Study

Thelle, D. S., Arnesen, E., & Førde, O. H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198306163082405 · Cited by 493 · see citing works

MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 ( <i>Srebp2</i> ) regulates HDL in vivo

Horie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384 · see citing works

Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant

Sirtori, C. R., Calabresi, L., Franceschini, G., Baldassarre, D., Amato, M., Johansson, J., Salvetti, M., Monteduro, C., Zulli, R., Muiesan, M. L., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1949 · Cited by 321 · see citing works

Genetic Variant of the Scavenger Receptor BI in Humans

Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317 · see citing works

Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.

Maeda, N., Li, H., Lee, D., Oliver, P. M., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · see citing works

Endothelial lipase is a major determinant of HDL level

Ishida, T., Choi, S. Y., Kundu, R. K., Hirata, K., Rubin, E. M., Cooper, A. D., & Quertermous, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16306 · Cited by 306 · see citing works

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

Bloedon, L. T., Dunbar, R. L., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., & Rader, D. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.p800003-jlr200 · Cited by 290 · see citing works

Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE

Bradley, M. N., Hong, C., Chen, M., Joseph, S. B., Wilpitz, D. C., Wang, X., Lusis, A. J., Collins, A., Hseuh, W. A., Collins, J. L., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31909 · Cited by 277 · see citing works

RVX-208

Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 233 · see citing works

A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome

Waksman, R., Torguson, R., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., Martin, B. D., Perlman, T. J., Maltais, J. B., Weissman, N. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.067 · Cited by 225 · see citing works

Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide

Datta, G., Chaddha, M., Hama, S. Y., Navab, M., Fogelman, A. M., Garber, D. W., Mishra, V., Epand, R. M., Epand, R. F., Lund‐Katz, S., et al. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31599-6 · Cited by 222 · see citing works

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

Katz, A., Udata, C., Ott, E., Hickey, L., Burczynski, M. E., Burghart, P. H., Vesterqvist, O., & Xu, M. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335768 · Cited by 218 · see citing works

Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography

Ballantyne, C. M., Raichlen, J. S., Nicholls, S. J., Erbel, R. M., Tardif, J., Brener, S. J., Cain, V. A., & Nissen, S. E. (2008) · Circulation · doi:10.1161/circulationaha.108.773747 · Cited by 200 · see citing works

Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans

Edmondson, A. C., Brown, R., Kathiresan, S., Cupples, L. A., Demissie, S., Manning, A. K., Jensen, M. K., Rimm, E. B., Wang, J., Rodrigues, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37176 · Cited by 193 · see citing works

Only the Two End Helixes of Eight Tandem Amphipathic Helical Domains of Human Apo A-I Have Significant Lipid Affinity

Palgunachari, M. N., Mishra, V., Lund‐Katz, S., Phillips, M. C., Adeyeye, S. O., Alluri, S., Anantharamaiah, G. M., & Segrest, J. P. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.2.328 · Cited by 192 · see citing works

Intestinal Specific LXR Activation Stimulates Reverse Cholesterol Transport and Protects from Atherosclerosis

Sasso, G. L., Murzilli, S., Salvatore, L., D’Errico, I., Petruzzelli, M., Conca, P., Jiang, Z., Calabresi, L., Parini, P., & Moschetta, A. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.07.002 · Cited by 189 · see citing works

Apolipoprotein-mediated Plasma Membrane Microsolubilization

Gillotte, K. L., Zaiou, M., Lund‐Katz, S., Anantharamaiah, G. M., Holvoet, P., Dhoest, A., Palgunachari, M. N., Segrest, J. P., Weisgraber, K. H., Rothblat, G. H., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.2021 · Cited by 183 · see citing works

Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis

Badellino, K. O., Wolfe, M. L., Reilly, M. P., & Rader, D. J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030022 · Cited by 173 · see citing works

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A. J., Borgman, M., & Nissen, S. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.015 · Cited by 170 · see citing works

Novel HDL-directed pharmacotherapeutic strategies

deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149 · see citing works

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function

Watson, C. E., Weissbach, N., Kjems, L., Ayalasomayajula, S. P., Zhang, Y., Chang, I., Navab, M., Hama, S. Y., Hough, G., Reddy, S. T., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m011098 · Cited by 149 · see citing works

Bile acid-activated receptors in the treatment of dyslipidemia and related disorders

Fiorucci, S., Cipriani, S., Baldelli, F., & Mencarelli, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.11.001 · Cited by 138 · see citing works

Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In Vivo

Yasuda, T., Grillot, D., Billheimer, J. T., Briand, F., Delerive, P., Huet, S., & Rader, D. J. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.195693 · Cited by 138 · see citing works

L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease

Ou, J., Ou, Z., Jones, D. W., Holzhauer, S., Hatoum, O. A., Ackerman, A. W., Weihrauch, D., Gutterman, D. D., Guice, K., Oldham, K. T., et al. (2003) · Circulation · doi:10.1161/01.cir.0000070589.61860.a9 · Cited by 138 · see citing works

Liver X Receptor Activation Controls Intracellular Cholesterol Trafficking and Esterification in Human Macrophages

Rigamonti, E., Helin, L., Lestavel, S., Mutka, A., Lepore, M., Fontaine, C., Bouhlel, M. A., Bultel, S., Fruchart, J., Ikonen, E., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000184678.43488.9f · Cited by 132 · see citing works

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

Bielicki, J. K., Zhang, H., Cortez, Y., Zheng, Y. Y., Narayanaswami, V., Patel, A., Johansson, J., & Azhar, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003665 · Cited by 126 · see citing works

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse

Quinet, E. M., Basso, M., Halpern, A. R., Yates, D. W., Steffan, R. J., Clerin, V. M., Resmini, C., Keith, J. C., Berrodin, T. J., Feingold, I. B., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900037-jlr200 · Cited by 111 · see citing works

The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins

Vedhachalam, C., Narayanaswami, V., Neto, N., Forte, T. M., Phillips, M. C., Lund‐Katz, S., & Bielicki, J. K. (2007) · Biochemistry · doi:10.1021/bi602407r · Cited by 106 · see citing works

Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor?

Rousset, X., Shamburek, R. D., Vaisman, B. L., Amar, M. J., & Remaley, A. T. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0171-6 · Cited by 105 · see citing works

Structure and Function of HDL Mimetics

Navab, M., Shechter, I., Anantharamaiah, G. M., Reddy, S. T., Lenten, B. J. V., & Fogelman, A. M. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.187518 · Cited by 104 · see citing works

Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type

Ibáñez, B., Giannarelli, C., Cimmino, G., Santos‐Gallego, C. G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimón, L., & Badimón, J. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.006 · Cited by 103 · see citing works

Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice

Hambruch, E., Miyazaki‐Anzai, S., Hahn, U. K., Matysik, S., Boettcher, A., Perović‐Ottstadt, S., Schlüter, T., Kinzel, O. D., Krol, H. D., Deuschle, U., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.196519 · Cited by 99 · see citing works

Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

Sacks, F. M., Rudel, L. L., Conner, A. P., Akeefe, H., Kostner, G. M., Baki, T. T., Rothblat, G. H., de la Llera-Moya, M., Asztalos, B. F., Perlman, T. J., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800622-jlr200 · Cited by 96 · see citing works

Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides

Sethi, A. A., Stonik, J. A., Fairwell, T., Demosky, S. J., Amar, M. J., Neufeld, E. B., Brewer, H. B., Davidson, W. S., D’Souza, W., Sviridov, D., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804461200 · Cited by 94 · see citing works

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 92 · see citing works

Apolipoprotein A-I Mimetic Peptides

Sherman, C. B., Peterson, S. J., & Frishman, W. H. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181c4b508 · Cited by 91 · see citing works

FXR an emerging therapeutic target for the treatment of atherosclerosis

Mencarelli, A., & Fiorucci, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00997.x · Cited by 90 · see citing works

Reverse cholesterol transport: High-density lipoprotein’s magnificent mile

Toth, P. P. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0010-5 · Cited by 87 · see citing works

The liver X receptor: Control of cellular lipid homeostasis and beyond

Oosterveer, M. H., Grefhorst, A., Groen, A. K., & Kuipers, F. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.03.002 · Cited by 71 · see citing works

Identification of an Apolipoprotein A-I Structural Element That Mediates Cellular Cholesterol Efflux and Stabilizes ATP Binding Cassette Transporter A1

Natarajan, P., Forte, T. M., Chu, B. M., Phillips, M. C., Oram, J. F., & Bielicki, J. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400561200 · Cited by 63 · see citing works

Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population

Tang, N., Wang, L., Yang, L., Zhou, B., Gu, H., Sun, Q., Cong, R.-H., Zhu, H., & Wang, B. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700399-jlr200 · Cited by 47 · see citing works

Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology?

Tardif, J. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.08.018 · Cited by 43 · see citing works

A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR–/– mice

Peng, D., Hiipakka, R. A., Xie, J., Dai, Q., Kokontis, J. M., Reardon, C. A., Getz, G. S., & Liao, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01202.x · Cited by 40 · see citing works

Reconstituted HDL in Acute Coronary Syndromes

Chenevard, R., Hürlimann, D., Spieker, L. E., Béchir, M., Enseleit, F., Hermann, M., Flammer, A. J., Sudano, I., Corti, R., Lüscher, T. F., et al. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00221.x · Cited by 37 · see citing works

Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence

Brown, B. G., Zhao, X.-Q., & Cheung, M. C. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.004 · Cited by 36 · see citing works

Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy

Asada, S., Kuroda, M., Aoyagi, Y., Fukaya, Y., Tanaka, S., Konno, S., Tanio, M., Aso, M., Satoh, K., Okamoto, Y., et al. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00080.2011 · Cited by 35 · see citing works

Targeting endogenous apo A-I—a new approach for raising HDL

Shah, P. K. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.37 · Cited by 18 · see citing works

Effects of curcumin on HDL functionality

Ganjali, S., Blesso, C. N., Banach, M., Pirro, M., Majeed, M., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.008 · Cited by 186 · see citing works

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 163 · see citing works

High density lipoprotein cholesterol and cancer: Marker or causative?

Pirro, M., Ricciuti, B., Rader, D. J., Catapano, A. L., Sahebkar, A., & Banach, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.06.001 · Cited by 107 · see citing works

Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study

Bartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96 · see citing works

Lipids, blood pressure and kidney update 2014

Banach, M., Aronow, W. S., Șerban, M.-C., Sahabkar, A., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.009 · Cited by 92 · see citing works

Subfractions and Subpopulations of HDL: An Update

Rizzo, M., Otvos, J. D., Nikolić, D., Montalto, G., Toth, P. P., & Banach, M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140414103455 · Cited by 84 · see citing works

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect

Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81 · see citing works

High‐density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin‐1

Lee, M. K. S., Moore, X., Fu, Y., Al‐Sharea, A., Dragoljevic, D., Fernandez-Rojo, M. A., Parton, R. G., Sviridov, D., Murphy, A. J., & Chin-Dusting, J. P. F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13319 · Cited by 80 · see citing works

Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease

Chruściel, P., Rysz, J., & Banach, M. (2014) · Drugs · doi:10.1007/s40265-014-0233-5 · Cited by 70 · see citing works

HDL abnormalities in familial hypercholesterolemia: Focus on biological functions.

Ganjali, S., Momtazi, A. A., Banach, M., Kovanen, P., Stein, E., & Sahebkar, A. (2017) · Progress in lipid research · doi:10.1016/j.plipres.2017.05.001 · Cited by 66 · see citing works

Evaluation of hypolipidemic peptide (Val-Phe-Val-Arg-Asn) virtual screened from chickpea peptides by pharmacophore model in high-fat diet-induced obese rat

Shi, W., Hou, T., Guo, D., & He, H. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.01.001 · Cited by 65 · see citing works

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes

Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 67 · see citing works

HDL particle number measured on the Vantera®, the first clinical NMR analyzer

Matyus, S. P., Braun, P. J., Wolak, J. E., Saenger, A. K., Jeyarajah, E. J., SHALAUROVA, I. Y., Warner, S. M., Fischer, T. J., & Connelly, M. A. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.11.017 · Cited by 63 · see citing works

HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target

Bhatt, A. B., & Rohatgi, A. K. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0554-1 · Cited by 62 · see citing works

High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment

Xu, R., Li, S., Li, X., Zhang, Y., Guo, Y., Zhu, C., Wu, N., Qing, P., Sun, J., Dong, Q., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.003 · Cited by 59 · see citing works

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study

Patti, A. M., Carruba, G., Cicero, A. F. G., Banach, M., Nikolić, D., Giglio, R. V., Terranova, A., Soresi, M., Giannitrapani, L., Montalto, G., et al. (2020) · Metabolites · doi:10.3390/metabo10100392 · Cited by 59 · see citing works

Lipids, blood pressure and kidney update 2015

Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57 · see citing works

Novel Therapeutical Approaches to Managing Atherosclerotic Risk

Giglio, R. V., Stoian, A. P., Al‐Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 54 · see citing works

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

Banerjee, Y., Pantea Stoian, A., Cicero, A. F. G., Fogacci, F., Nikolic, D., Sachinidis, A., Rizvi, A. A., Janez, A., & Rizzo, M. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1988568 · Cited by 54 · see citing works

Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications

Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48 · see citing works

Chronic consumption of a low-fat diet improves cardiometabolic risk factors according to the CLOCK gene in patients with coronary heart disease

Gómez-Delgado, F., García‐Ríos, A., Alcala-Diaz, J. F., Rangel-Zúñiga, O. A., Delgado‐Lista, J., Yubero‐Serrano, E. M., López-Moreno, J., Tinahones, F. J., Ordovás, J. M., Garaulet, M., et al. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500375 · Cited by 47 · see citing works

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis

Chyu, K., & Shah, P. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00187 · Cited by 43 · see citing works

Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy

Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 43 · see citing works

The Role of Endothelium in COVID-19

Ionescu, M., Stoian, A. P., Rizzo, M., Şerban, D., Nuzzo, D., Mazilu, L., Suceveanu, A., Dascălu, A. M., & Parepa, I. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111920 · Cited by 39 · see citing works

Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study

Raimondo, S., Nikolić, D., Conigliaro, A., Giavaresi, G., Sasso, B. L., Giglio, R. V., Chianetta, R., Manno, M., Raccosta, S., Corleone, V., et al. (2021) · Metabolites · doi:10.3390/metabo11050276 · Cited by 37 · see citing works

2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland

Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36 · see citing works

Low Levels of Blood Lipids Are Associated with Etiology and Lethal Outcome in Acute Liver Failure

Manka, P. P., Olliges, V., Bechmann, L. P., Schlattjan, M., Jochum, C., Treckmann, J. W., Saner, F. H., Gerken, G., Syn, W., & Canbay, A. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102351 · Cited by 35 · see citing works

An evaluation of RVX-208 for the treatment of atherosclerosis

Nikolić, D., Rizzo, M., Mikhailidis, D. P., Wong, N. C. W., & Banach, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1083010 · Cited by 35 · see citing works

The interaction between uric acid and high-density lipoprotein cholesterol on the prognosis of patients with acute myocardial infarction

Yang, Y., Zhang, J., Jia, L., Su, J.-N., Ma, M., & Lin, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1226108 · Cited by 34 · see citing works

Effect of pumpkin seed oil on cholesterol fractions and systolic/diastolic blood pressure

MAJID, A. K., AHMED, Z., & KHAN, R. (2020) · Food Science and Technology · doi:10.1590/fst.03720 · Cited by 34 · see citing works

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study

Giglio, R. V., Carruba, G., Cicero, A. F. G., Banach, M., Patti, A. M., Nikolić, D., Cocciadiferro, L., Zarcone, M., Montalto, G., Stoian, A. P., et al. (2020) · Metabolites · doi:10.3390/metabo10110428 · Cited by 34 · see citing works

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

Giglio, R. V., Stoian, A. P., Haluzı́k, M., Pafili, K., Patti, A. M., Rizvi, A. A., Ciaccio, M., Παπάνας, Ν., & Rizzo, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166148 · Cited by 26 · see citing works

Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction

Park, J. S., Cha, K. S., Lee, H. W., Oh, J., Choi, J. H., Lee, H. C., Hong, T. J., Jeong, M. H., Chae, S. C., & Kim, Y. (2013) · Cardiology Journal · doi:10.5603/cj.a2018.0020 · Cited by 26 · see citing works

Dysfunctional HDL: the journey from savior to slayer

Serban, C., Muntean, D. M., Mikhailids, D. P., Toth, P. P., & Banach, M. (2014) · Clinical Lipidology · doi:10.2217/clp.13.83 · Cited by 23 · see citing works

Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study

Chruściel, P., Stemplewska, P., Stemplewski, A., Wattad, M., Bielecka-Dabrowa, A. M., Maciejewski, M., Penson, P. E., Bartłomiejczyk, M. A., & Banach, M. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.86197 · Cited by 25 · see citing works

Effects of epigallocatechin gallate on total antioxidant capacity, biomarkers of systemic low-grade inflammation and metabolic risk factors in patients with type 2 diabetes mellitus: the role of FTO-rs9939609 polymorphism

Hosseini, S. A., Alipour, M., Zakerkish, M., Cheraghian, B., & Ghandil, P. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.95903 · Cited by 21 · see citing works

Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease

Xu, R., Zhang, Y., Ye, P., Chen, H., Li, Y., Hua, Q., Guo, Y., Li, X., Li, S., Dong, Q., et al. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.05.002 · Cited by 21 · see citing works

Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond

Bartolo, B. A. D., Scherer, D. J., & Nicholls, S. J. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.62906 · Cited by 19 · see citing works

Novel therapies for severe dyslipidemia originating from human genetics

Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18 · see citing works

Dietary niacin requirement of juvenile blunt snout breamMegalobrama amblycephalabased on a dose-response study

Li, X., Wang, T., Yu, Q., Jiang, G., Zhang, D.-D., & Liu, W. (2017) · Aquaculture Nutrition · doi:10.1111/anu.12516 · Cited by 18 · see citing works

Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis

Chin, D. D., Patel, N., Lee, W., Kanaya, S., Cook, J., & Chung, E. J. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.04.001 · Cited by 17 · see citing works

Closed-loop regulation of arterial pressure after acute brain death

Soltesz, K., Sjöberg, T., Jansson, T. T., Johansson, R., Robertsson, A., Paskevicius, A., Liao, Q., Qin, G., & Steen, S. (2017) · Journal of Clinical Monitoring and Computing · doi:10.1007/s10877-017-0033-z · Cited by 16 · see citing works

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL

Cao, P., Pan, H., Xiao, T., Zhou, T., Guo, J., & Su, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817245 · Cited by 15 · see citing works

High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study

Nazari, S. S. H., Shakiba, M., Khalili, D., Hadaegh, F., Tohidi, M., & Azizi, F. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.04.001 · Cited by 15 · see citing works

Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques

Roddy, T. P., McLaren, D. G., Chen, Y., Xie, D., Dunn, K., Kulick, A. A., Szeto, D., Forrest, G., Albanese, K., Donnelly, M. J., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.04.015 · Cited by 13 · see citing works

Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis

Xu, R., Zhang, Y., Zhang, Y., Wu, Y., Li, X., Guo, Y., Liu, G., Dong, Q., & Li, J. (2020) · Current Medical Science · doi:10.1007/s11596-020-2263-4 · Cited by 13 · see citing works

HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation

Παπαγεωργίου, Ν., Zacharia, E. M., Androulakis, E. S., Briasoulis, Α., Charakida, M., & Tousoulis, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1152264 · Cited by 11 · see citing works

Pulmonary hypertension is not a risk factor for grade 3 primary graft dysfunction after lung transplantation

Cottini, S. R., Brandi, G., Pagnamenta, A., Weder, W., Schuepbach, R. A., Béchir, M., Huber, L., & Benden, C. (2018) · Clinical Transplantation · doi:10.1111/ctr.13251 · Cited by 11 · see citing works

Novel findings in relation to multiple anti‐atherosclerotic effects of XueZhiKang in humans

Xu, R., Zhang, Y., Guo, Y., Ma, C., Yao, Y., Li, S., Li, X., Qing, P., Gao, Y., Wu, N., et al. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.09.004 · Cited by 10 · see citing works

Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease

Zhao, X., Zhang, H., Sun, D., Xu, R., Guo, Y., Sun, J., Zhu, C., Wu, N., Zhang, Y., Li, S., et al. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106345 · Cited by 10 · see citing works

Pretransplant dyslipidaemia influences primary graft dysfunction after lung transplantation

Cottini, S. R., Ehlers, U. E., Pagnamenta, A., Brandi, G., Weder, W., Schuepbach, R. A., Béchir, M., & Benden, C. (2015) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivv295 · Cited by 9 · see citing works

The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8 · see citing works

Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease

Xu, R., Zhang, Y., Li, X., Li, S., Guo, Y., Dong, Q., Liu, G., & Li, J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.032 · Cited by 8 · see citing works

Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective

Fras, Z., Jug, B., Penson, P. E., & Rizzo, M. (2021) · Metabolites · doi:10.3390/metabo11090611 · Cited by 7 · see citing works

Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis

Bartolo, B. A. D., Schwarz, N., Andrews, J., & Nicholls, S. J. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60941 · Cited by 6 · see citing works

Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review

Nourizadeh, N., Mostaan, L. V., Saburi, E., & Hashemy, S. I. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07623-7 · Cited by 6 · see citing works

Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population

Włodarczyk, M., Wrzosek, M., Nowicka, G., & Jabłonowska-Lietz, B. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60870 · Cited by 6 · see citing works

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?

Lan, N. S. R., & Watts, G. F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01281-3 · Cited by 5 · see citing works

The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy

Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5 · see citing works

Effects of Hedan Tablet (荷丹片) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study

Xu, R., Wu, N., Li, S., Zhang, Y., Li, X.-L., Guo, Y., Zhu, C., Liu, G., Dong, Q., & Li, J. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2140-3 · Cited by 4 · see citing works

JCL Roundtable: HDL in the primary care setting

Brown, W. V., Ansell, B. J., Mackey, R. H., & Toth, P. P. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.05.009 · Cited by 4 · see citing works

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

Nikolić, D., Katsiki, N., Toth, P. P., Banach, M., Al-Waili, K., Al‐Rasadi, K., Rizzo, M., & Mikhailidis, D. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_15 · Cited by 2 · see citing works

Ethnicity and coronary artery disease: the role of high-density lipoprotein – a change in paradigm

Bravo‐Jaimes, K., & Velarde, G. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1065178 · Cited by 2 · see citing works

Epicardial, peripancreatic and other “orthotopic” excessive fat deposition in south Asians and Europeans: Are differences clinically relevant?

Katsiki, N., Rizzo, M., & Mikhailidis, D. P. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108419 · Cited by 2 · see citing works

Unraveling the Anti‐Obesity Potential of White Kidney Bean α‐Amylase Inhibitors: Mechanistic Insights From Enzyme Kinetics to Gut Microbiota Modulation

Yan, J., Zhao, J., Naizemuding, P., Zhao, W., Sun, J., Wang, Y., Yang, J., Li, D., Zhang, F., & Cao, H. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.71043 · Cited by 1 · see citing works

Optical Properties of Europium Tetracycline Complexes in the Presence of High-Density Lipoproteins (HDL) Subfractions

Sicchieri, L. B., Monteiro, A. M., Neto, A. M. F., Gomes, L., & Courrol, L. C. (2016) · Applied Spectroscopy · doi:10.1177/0003702816683685

High-Density Lipoprotein: From Biological Functions to Clinical Perspectives

Liu, D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91136

Emerging Therapies For Raising Hdl-C And Augmenting Hdl Particle Functionality

Barylski, M., Toth, P., Dragana, N., Banach, M., MONTALTO, G., & RIZZO, M. (2013) · Nova Science Publishers (Nova Science Publishers, Inc.)

Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis

Kontush, A., & Chapman, M. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.1 · Cited by 752 · see citing works

Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?

Dragan, S. R., Șerban, M.-C., & Banach, M. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140303153829 · Cited by 21 · see citing works

Therapeutic approaches for the modification of high-density lipoproteins

von Eckardstein, A. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.09.004 · Cited by 8 · see citing works

Pharmacomodulation of High-Density Lipoprotein Metabolism as a Therapeutic Intervention for Atherosclerotic Disease

Toth, P. P. (2010) · Current Cardiology Reports · doi:10.1007/s11886-010-0136-3 · Cited by 12 · see citing works